Heart Failure GDMT in Children

Mostly extrapolated from adults. Most pediatric rows are Level C. Only sacubitril/valsartan (≥1 year), ivabradine (≥6 months), digoxin and furosemide carry a US label for heart failure in children; every other pediatric use is off-label.

Drug class

Drug classes in HFrEF

Children: ISHLT 2025, biventricular circulation with a systemic LV. Adult: AHA/ACC/HFSA 2022.
ClassChildren (ISHLT 2025)Adult HFrEF (AHA 2022)
IB LV systolic dysfunction, routinelyIA when ARNi is not feasible
IIaC ACE inhibitor not toleratedIA ACEi intolerant, ARNi not feasible
IIaB symptomatic, in place of ACE inhibitor or ARBIA NYHA II–III
IIaC systemic LV systolic dysfunctionIA bisoprolol, carvedilol, metoprolol succinate
IIaC symptomatic systemic LV dysfunctionIA eGFR >30, potassium <5.0 mEq/L
IIbC symptomatic; not systematically studiedIA
IIaB stable, heart-rate reduction wantedIIaB-R sinus rhythm, HR ≥70 on beta-blocker
IIbC symptoms, level e.g. 0.5–0.9 ng/mlIIbB-R
IC fluid retention, to euvolemiaIB-NR
IIbC worsening despite optimized GDMTIIbB-R
IIaB iron deficiencyIIaB-R
IIbC ACE inhibitor or ARB. Beta-blocker: caution (text, not graded)Not covered here
ACE inhibitor, ARB

ACE inhibitor, ARB

Children
ACE inhibitor routinely in LV systolic dysfunction unless contraindicated (I, B); ARB if an ACE inhibitor is not tolerated (IIa, C) (ISHLT 2025; no pediatric RCT of either, its text)
Pediatric dose
No source read gives a pediatric heart failure dose (CCS 2013 puts ACE inhibitor doses in an online supplement, not read). Label doses below are for hypertension:
  • Enalapril: 0.08 mg/kg (up to 5 mg) once daily; above 0.58 mg/kg (or 40 mg) not studied. Not in neonates, preterm infants before 44 weeks post-conceptual age, or GFR <30 mL/min/1.73 m² (Epaned §2.1)
  • Valsartan, 1–16 years: 1 mg/kg once daily (up to 40 mg); maximum 4 mg/kg once daily (160 mg/day); not under 1 year; no data with GFR <30 (Diovan §2.3)
  • Losartan, ≥6 years: 0.7 mg/kg once daily (up to 50 mg); above 1.4 mg/kg (or 100 mg) not studied; not with eGFR <30 (Cozaar §2.1)
  • Captopril: no pediatric dose printed; infants, especially newborns, may have excessive, prolonged hypotension with oliguria and seizures (captopril label)
Adult start → target
Enalapril 2.5 mg twice daily → 10–20 mg twice daily; captopril 6.25 mg 3 times daily → 50 mg 3 times daily; lisinopril 2.5–5 → 20–40 mg once daily; losartan 25–50 → 50–150 mg once daily; valsartan 20–40 mg once daily → 160 mg twice daily; candesartan 4–8 → 32 mg once daily (AHA 2022 Table 14; ESC 2021 Table 8 differs: lisinopril target 20–35 mg, losartan 50 → 150 mg, valsartan start 40 mg twice daily)
Cautions
Low blood pressure, renal insufficiency, potassium >5.0 mEq/L; do not stop an ACE inhibitor abruptly (AHA 2022, Adult)
Never
ACE inhibitor with any history of angioedema (AHA III: Harm, Adult); with sacubitril/valsartan or within 36 hours of it (Epaned §4); ACE inhibitor + ARB + MRA together (ESC III, C, Adult)

Graded rows

ISHLT 2025 §4.2, children
ClassRecommendationLOE
ILV systolic dysfunction: ACE inhibitor routinely, unless specifically contraindicatedB
IIaSystemic ventricular dysfunction, ACE inhibitor not tolerated: ARB is a reasonable alternativeC
CCS 2013 F4, children; GRADE strength and quality
StrengthRecommendationQuality
StrongHeart failure from primary heart-muscle disease of the systemic LV: ACE inhibitor indicatedModerate

CCS 2013 text: ARB therapy in children with heart failure is untested; it gives no graded ARB recommendation.

AHA 2022 §7.3.1 and ESC 2021 §5.3–5.4 Adult
ClassRecommendationLOE
IAHA: chronic HFrEF, ARNi not feasible: ACE inhibitorA
IAHA: ACE inhibitor intolerant (cough, angioedema), ARNi not feasible: ARBA
III: HarmAHA: ACE inhibitor with any history of angioedemaC-LD
IESC: ACE inhibitor to reduce heart failure hospitalization and deathA
IESC: ARB if an ACE inhibitor or ARNI is not tolerated (candesartan, losartan, valsartan)B
Sacubitril/valsartan

Sacubitril/valsartan (ARNI)

Children
Symptomatic systemic LV systolic dysfunction: in place of an ACE inhibitor or ARB (IIa, B) (ISHLT 2025). US label: ≥1 year; data under 1 year inadequate (Entresto §1.2, §8.4)
Pediatric dose
Twice daily; step up every 2 weeks as tolerated (Entresto §2.3). mg/kg is the combined sacubitril + valsartan amount.
Entresto label §2.3 Table 1, tablets or oral suspension, twice daily
WeightStartSecondFinal
<40 kg (suspension or pellets)1.6 mg/kg2.3 mg/kg3.1 mg/kg
40 to <50 kg24/26 mg49/51 mg72/78 mg
≥50 kg49/51 mg72/78 mg97/103 mg
Oral pellets by weight (Entresto Sprinkle)
Entresto label §2.3 Table 2, twice daily; under 13 kg use the oral suspension; ≥50 kg use Table 1
WeightStartSecondFinal
13 to <19 kg12/12 mg18/18 mg24/24 mg
19 to <26 kg18/18 mg24/24 mg30/32 mg
26 to <34 kg24/24 mg30/32 mg45/48 mg
34 to <50 kg30/32 mg45/48 mg60/64 mg

Pellets: open the capsule onto 1–2 teaspoons of soft food; do not chew or crush; never through a nasogastric, gastrostomy or other enteral tube (§2.5). Suspension 4 mg/mL from eight 49/51 mg tablets, kept up to 15 days, not refrigerated (§2.4).

Half start
Not on an ACE inhibitor or ARB, or on a low dose; eGFR <30 mL/min/1.73 m²; moderate hepatic impairment (Child-Pugh B). In these groups 40–50 kg starts at 0.8 mg/kg twice daily. Severe hepatic impairment: not recommended (§2.6–2.8)
Switching
Stop the ACE inhibitor 36 hours before the first dose; wait 36 hours after the last dose before an ACE inhibitor (§2.1, §4; Epaned §4)
Never
With an ACE inhibitor; history of angioedema with an ACE inhibitor or ARB; with aliskiren in diabetes (§4)
Check
Blood pressure, creatinine, potassium; reduce or interrupt for hypotension, a significant creatinine rise or hyperkalemia (§5.3–5.5)
Adult start → target
49/51 mg → 97/103 mg twice daily; may start at 24/26 mg (AHA 2022 Table 14)
Trial
PANORAMA-HF, 375 children 1 month to <18 years, systemic LV: no superiority over enalapril at 52 weeks (Mann-Whitney odds 0.91, 95% CI 0.72–1.14); both arms improved. Target 3.1 mg/kg twice daily from 1 year, 2.3 mg/kg in age group 3 (1 month to <1 year as randomized). Single ventricle, systemic RV, restrictive and hypertrophic cardiomyopathy were excluded (Shaddy 2024)

Graded rows

ISHLT 2025 §4.3, children; AHA 2022 §7.3.1 and ESC 2021 §5.3, Adult
ClassRecommendationLOE
IIaISHLT: symptomatic systemic LV systolic dysfunction: ARNI in place of an ACE inhibitor or ARBB
IAHA Adult HFrEF, NYHA II–III: ARNiA
IAHA Adult NYHA II–III tolerating an ACE inhibitor or ARB: replace it with ARNiB-R
III: HarmAHA Adult ARNi with an ACE inhibitor or within 36 hours of the last doseB-R
III: HarmAHA Adult ARNi with any history of angioedemaC-LD
IESC Adult sacubitril/valsartan as a replacement for an ACE inhibitorB
Beta-blocker

Beta-blocker

Children
Systemic LV systolic dysfunction (IIa, C) (ISHLT 2025). Single ventricle or systemic RV: caution
Pediatric dose
No label: carvedilol effectiveness under 18 years not established (Coreg §8.4). Carvedilol start 0.05 mg/kg every 12 hours; every 8 hours favoured under 4 years (dose per administration then not printed); no target printed (CCS 2013). Trial targets (not a recommendation): 0.2 or 0.4 mg/kg per dose twice daily under 62.5 kg, 12.5 or 25 mg per dose at ≥62.5 kg, titrated as tolerated every 2 weeks through 4 levels, then the maximum tolerated or target dose kept for 6 months; achieved doses not reported; no significant benefit on the composite outcome (Shaddy 2007). The CCS start and the trial targets come from different sources and are not one regimen.
Adult start → target
Carvedilol 3.125 mg twice daily → 25–50 mg twice daily; metoprolol succinate 12.5–25 → 200 mg once daily; bisoprolol 1.25 → 10 mg once daily (AHA 2022 Table 14; ESC 2021 Table 8: carvedilol 25 mg twice daily, 50 mg over 85 kg)
Start
When stable, euvolemic and off IV inotropes; do not stop abruptly (AHA 2022, ESC 2021, Adult). Dobutamine with caution in children on beta-blockers (ISHLT 2025, acute)

Graded rows

ISHLT 2025 §4.4; AHA 2022 §7.3.2; ESC 2021 §5.3
ClassRecommendationLOE
IIaISHLT: children with systemic LV systolic dysfunction C
IAHA Adult bisoprolol, carvedilol or metoprolol succinate; not a class effectA
IESC Adult stable HFrEFA
CCS 2013 F5, children; GRADE strength and quality
StrengthRecommendationQuality
ConditionalModerate to severe systolic dysfunction of a systemic LV: carvedilol, metoprolol or bisoprolol might be startedModerate
MRA

Mineralocorticoid receptor antagonist (MRA)

Children
Symptomatic systemic LV dysfunction (IIa, C) (ISHLT 2025). With RV-morphology single ventricle MRAs may not be effective (AHA 2024, not graded)
Pediatric dose
Spironolactone start 1 mg/kg/day, target maximum 2 mg/kg/day; frequency not printed (CCS 2013). Not established in children by label (Aldactone, CaroSpir, Inspra §8.4); no pediatric eplerenone dose read
Adult start → target
Spironolactone 12.5–25 → 25–50 mg once daily; eplerenone 25 → 50 mg once daily (AHA 2022 Table 14; its text says start 25 mg. ESC 2021: spironolactone 25 mg, optionally 12.5, → 50 mg)
Start only if
eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L; eGFR 31–49: half dose (AHA 2022, Adult)
Check
Children: potassium and renal function before starting, within 7–14 days, then periodically; watch for gynecomastia in boys (CCS 2013). Adult at about 1 week, 4 weeks, then every 6 months; consider holding with diarrhea or dehydration (AHA 2022)
Stop
If potassium cannot be kept <5.5 mEq/L (AHA III: Harm, Adult). Spironolactone with sacubitril/valsartan can raise potassium (Entresto §5.5, §7.2)

Graded rows

ISHLT 2025 §4.2; AHA 2022 §7.3.3; ESC 2021 §5.3
ClassRecommendationLOE
IIaISHLT: children with symptomatic systemic LV dysfunctionC
IAHA Adult NYHA II–IV, eGFR >30 and potassium <5.0 mEq/LA
III: HarmAHA Adult continuing when potassium cannot be kept <5.5 mEq/LB-NR
IESC Adult MRA in HFrEFA
CCS 2013 F6, children; GRADE strength and quality
StrengthRecommendationQuality
ConditionalChronic systolic heart failure with normal or mildly impaired renal function; watch renal function and potassium closely with an ACE inhibitorLow
SGLT2 inhibitor

SGLT2 inhibitor

Children
Symptomatic HFrEF: may be considered; not systematically studied (IIb, C) (ISHLT 2025). The pediatric study it cites: dapagliflozin in 38 nondiabetic patients, 3 months to 21 years, on GDMT; BNP improved; 4 acute kidney injury, 6 symptomatic urinary tract infection (observational)
Pediatric dose
None for heart failure; the labels limit heart failure to adults and label children only for type 2 diabetes from 10 years (Farxiga, Jardiance §1, §8.4)
Adult dose
Dapagliflozin 10 mg once daily; empagliflozin 10 mg once daily (AHA 2022 Table 14, ESC 2021 Table 8)
Cautions
Euglycemic ketoacidosis, genital and soft-tissue infection, volume depletion (adjust the diuretic); a small reversible eGFR fall is expected. Trials excluded eGFR <20 (EMPEROR-Reduced) or <30 mL/min/1.73 m² (DAPA-HF) (AHA 2022, ESC 2021, Adult)

Graded rows

ISHLT 2025 §4.7; AHA 2022 §7.3.4; ESC 2021 §5.3
ClassRecommendationLOE
IIbISHLT: children with symptomatic HFrEFC
IAHA Adult symptomatic chronic HFrEF, with or without type 2 diabetesA
IESC Adult dapagliflozin or empagliflozinA
Ivabradine

Ivabradine

Children
Stable heart failure when heart-rate reduction is wanted (IIa, B) (ISHLT 2025). US label: stable symptomatic heart failure from DCM, ≥6 months, sinus rhythm with an elevated heart rate (Corlanor §1.2)
Corlanor label §2.2, twice daily with food; review every 2 weeks
GroupStartStepMaximum
<40 kg (oral solution 1 mg/mL)0.05 mg/kg0.05 mg/kg0.2 mg/kg (6 months to <1 year); 0.3 mg/kg (≥1 year); never above 7.5 mg
≥40 kg (tablets)2.5 mg2.5 mg7.5 mg
Aim
Heart rate at least 20% lower, as tolerated; the label gives no target rate by age (§2.2)
Bradycardia
Go back one step; at the first dose consider 0.02 mg/kg twice daily (§2.2)
Never
Acute decompensated heart failure; significant hypotension or bradycardia; sick sinus, sinoatrial block or third-degree AV block without a demand pacemaker; pacemaker dependence; severe hepatic impairment; strong CYP3A4 inhibitors (§4). Stop if atrial fibrillation starts; avoid verapamil and diltiazem (§5.2–5.3)
Trial entry
Resting heart rate ≥105 (6–12 months), ≥95 (1–3 years), ≥75 (3–5 years), ≥70/min (5–18 years); LVEF ≤45%. Entry criteria, not targets (§14.2)
Adult start → target
5 mg → 7.5 mg twice daily; sinus rhythm, resting heart rate ≥70/min, LVEF ≤35%, on a maximally tolerated beta-blocker (AHA 2022)

Graded rows

ISHLT 2025 §4.6; AHA 2022 §7.3.9.1; ESC 2021 §5.4
ClassRecommendationLOE
IIaISHLT: children with stable heart failure when heart-rate reduction is desirableB
IIaAHA Adult NYHA II–III, LVEF ≤35%, sinus rhythm, resting heart rate ≥70 on a maximally tolerated beta-blockerB-R
IIaESC Adult LVEF ≤35%, sinus rhythm, resting heart rate ≥70 despite beta-blocker, ACE inhibitor (or ARNI) and MRAB
IIaESC Adult the same, when a beta-blocker is not tolerated or contraindicatedC
Digoxin

Digoxin

Children
Symptomatic HFrEF, for symptoms, at lower serum levels, e.g. 0.5–0.9 ng/ml (IIb, C) (ISHLT 2025). Our note: the label regimens below were not set for that lower level; dose to the level. Single ventricle after stage 1 palliation, no arrhythmia history: digoxin at discharge was associated with lower interstage mortality (AHA 2024, observational data it cites)
Digoxin oral solution 50 mcg/mL label §2.3–2.4 Tables 1–2 (Hikma), normal renal function
AgeMaintenance, mcg/kg per doseTotal oral load, mcg/kg
Premature2.3–3.9 twice daily20–30
Full-term3.8–5.6 twice daily25–35
1–24 months5.6–9.4 twice daily35–60
2–5 years4.7–6.6 twice daily30–45
5–10 years2.8–5.6 twice daily20–35
Over 10 years3.0–4.5 once daily10–15
Load
About half the total first, the rest in fractions every 4–8 hours, checking response before each (solution label §2.3). Without a load, steady state in about 5 days with normal renal function
Tablets differ
Lanoxin tablets: 5–10 years 3.2–6.4 mcg/kg per dose twice daily, load 20–45; over 10 years 3.4–5.1 mcg/kg/day (Lanoxin §2.2–2.4). Name the product when you dose
Renal
Lower doses and frequent levels; both labels tabulate doses by creatinine clearance (Schwartz in children)
Level
Just before the next dose or ≥6 hours after. <0.5 ng/mL: less effect; >2 ng/mL: toxicity without more benefit (labels). Adult aim 0.5–<0.9 (AHA 2022) or <1.2 ng/mL (ESC 2021)
Toxicity
In children the first sign is usually an arrhythmia, including sinus bradycardia: treat any new arrhythmia or conduction change as toxicity first (Lanoxin §5.3)

Graded rows

ISHLT 2025 §4.5; AHA 2022 §7.3.9.2; ESC 2021 §5.4
ClassRecommendationLOE
IIbISHLT: symptomatic HFrEF, for symptoms, at lower serum levels (e.g. 0.5–0.9 ng/ml)C
IIbAHA Adult symptomatic despite GDMT, to reduce hospitalizationB-R
IIbESC Adult sinus rhythm, symptomatic despite ACE inhibitor (or ARNI), beta-blocker and MRAB
Diuretics

Diuretics

Children
Fluid retention with ventricular dysfunction: diuretics to euvolemia (I, C) (ISHLT 2025). Loop diuretic preferred; add a thiazide for a limited loop response or to prevent calciuria and nephrocalcinosis from long-term loop use (AHA 2024)
Acute, congested
Furosemide 0.5–1 mg/kg IV or oral every 6–12 hours to start (CCS 2013 F1, strong, moderate quality)
Furosemide oral
2 mg/kg once; if the response is poor, a dose 1–2 mg/kg larger, no sooner than 6–8 hours after the previous one; above 6 mg/kg not recommended; keep the lowest effective dose (Lasix tablets and furosemide oral solution labels)
Furosemide IV or IM
1 mg/kg over 1–2 minutes; if needed, a dose 1 mg/kg larger, no sooner than 2 hours after the previous one; above 6 mg/kg not recommended; premature infants at most 1 mg/kg/day (furosemide injection §2.3)
Watch
Ototoxicity in preterm infants under 31 weeks post-conceptual age given >1 mg/kg/24 h; nephrocalcinosis in preterm infants and children under 4 years on long-term therapy (renal ultrasound) (labels)
Adult
Furosemide 20–40 mg once or twice daily, maximum 600 mg/day (AHA 2022 Table 12)

Graded rows

ISHLT 2025 §4.1; AHA 2022 §7.2; ESC 2021 §5.4
ClassRecommendationLOE
IISHLT: fluid retention with ventricular dysfunction (stage C): diuretics to euvolemiaC
IAHA Adult fluid retention: diuretics to relieve congestionB-NR
IAHA Adult add a thiazide only when moderate- or high-dose loop diuretics failB-NR
IESC Adult loop diuretic for congestionC
Vericiguat, iron, other

Vericiguat, iron, anticoagulation, hydralazine-nitrate

Vericiguat
Children: add-on when heart failure worsens despite dose-optimized beta-blocker, ACE inhibitor or ARNI, and MRA (IIb, C); no published pediatric use, a trial (VALOR) is running (ISHLT 2025). Adult 2.5 → 10 mg once daily (AHA 2022 Table 14); AHA IIb, B-R; ESC IIb, B
Iron
Children: screen for anemia (I, C) and iron deficiency (I, B); IV iron is reasonable (IIa, B). Deficiency is ≥2 of serum iron <50 μg/dl, ferritin <20 ng/ml, transferrin >300 ng/ml (unit as printed), transferrin saturation <15% (ISHLT 2025 §9.1). Oral iron has low efficacy in children (AHA 2024). Adult IV ferric carboxymaltose for symptomatic LVEF <45% with ferritin <100 ng/mL, or 100–299 with saturation <20% (ESC 2021 IIa, A)
Anticoagulation
Intracardiac thrombus (I, B); prior thrombus or thromboembolism with EF <25% (FS <15%) (IIa, C); low EF with persistent or uncontrolled paroxysmal atrial fibrillation or flutter (IIa, C) (ISHLT 2025 §4.10). Agents and targets: Antithrombotic Therapy
Hydralazine-nitrate
Not in the pediatric sources. Adult self-identified African American, NYHA III–IV on optimal therapy (AHA I, A); unable to take ARNi, ACE inhibitor or ARB (AHA IIb, C-LD)
Avoid
Adult nondihydropyridine calcium channel blockers, class IC antiarrhythmics and dronedarone, thiazolidinediones, NSAIDs (AHA III: Harm)
Systemic RV, single ventricle

Systemic RV and single ventricle

Graded
Ventricular dysfunction: ACE inhibitor or ARB may be considered (IIb, C); symptomatic dysfunction: referral to an advanced heart failure and transplant specialist is reasonable (IIa, B) (ISHLT 2025 §6.1)
Beta-blocker
Caution: in the pediatric carvedilol trial a non-LV systemic ventricle trended worse than placebo, a systemic LV better (interaction P = .02) (ISHLT 2025 and AHA 2024 text; Shaddy 2007)
AHA 2024
Not graded. Systemic RV: medical therapy case by case; dysfunction means RVEF <40% by MRI or more than moderately reduced by echo. The enalapril RCT in infants with a single ventricle and normal to mildly reduced EF showed no benefit. MRAs may not work in a single ventricle with RV morphology
Not covered
Neither source gives Fontan-specific or atrial-switch- or ccTGA-specific GDMT. These patients were excluded from PANORAMA-HF; the ivabradine trial was DCM only
Titration and monitoring

Titration and monitoring

Order
No pediatric source sets a starting order; ISHLT 2025 asks for a plan (which drug first, starting dose, uptitration, target, when to add) and puts tolerance before reaching the target dose. Adult order and simultaneous starts are individualized and should not delay therapy (AHA 2022); ACE inhibitor and beta-blocker can start together (ESC 2021)
Interval
Every 2 weeks for pediatric sacubitril/valsartan and ivabradine (labels); Adult as often as every 1–2 weeks (AHA IIa, C-EO)
Labs
Renal function at diagnosis, at regular intervals and after changes in therapy (I, B); BNP or NT-proBNP to follow known heart failure (I, B), no target printed (ISHLT 2025)
Visits
Stage B every 6–12 months; stage C every 3–6 months with BNP or NT-proBNP, liver and renal function; stage D every 4–6 weeks (AHA 2024 Figure 3, CHD)
Creatinine
Adult after starting a RAAS inhibitor, ARNI or SGLT2 inhibitor, a creatinine rise <50% (while <3 mg/dL) or an eGFR fall <10% (while >25) should not stop therapy (ESC 2021 §13.6)
In hospital
Adult continue GDMT; do not stop it for a mild creatinine rise or an asymptomatic fall in blood pressure (AHA I, B-NR)

Chronic HFrEF in children: class by class, pediatric doses only where a label, guideline or trial prints one; adult grades and doses labelled

Key points

Sources and how this page was checked

Full text read

How it was checked

Not covered on this page